Major Depression research hub

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder - SM-1

This study is looking at a new medication, REL-1017, to help people with major depression who haven't fully improved with their current treatment. It's comparing the new drug to a dummy pill to see if it makes a difference to their mood.